Business Description
Pharmicell Co., Ltd. is a South Korea-based biopharmaceutical company founded in 1968 that specializes in developing and commercializing therapies derived from a patient's own stem cells. Its lead product, Cellgram-AMI, uses bone marrow-derived stem cells to support heart recovery following a heart attack, while additional treatments targeting liver disease and erectile dysfunction are currently in development. The company also produces chemical intermediates and cell culture media, and operates a stem cell banking service under the Twelve brand.
